covance companion diagnostics development: strong solutions from the right partner
TRANSCRIPT
Companion diagnostiCsdevelopment is Changing
do YoU have theRight solUtionsand paRtneR?
Products and industries once consideredseparate have become integrated.
Todayintegrated
Yesterdayparallel
Tomorrowseamless
Dis
co
ve
ryD
isco
ve
ry
Biomarker/Cdx developmentdrug development
Dis
co
ve
ry
Co
mm
erc
ializ
atio
n
Co
mm
erc
ializ
atio
n
Co
mm
erc
ializ
atio
n
time
time
Preclinical
BiomarkerDevelopment
CDx Assay& Feasibility
CDx Development& Validation
Regulatory Submission& CDx Launch
Phase I Phase III NDASubmissionPhase II
Number of studies conducted by Covance in the last 5 years
Investigatorsprefer Covance 2X
Global footprintand experience
Proven resultsat every stage
CovanCe
Competitor A
Competitor B
Competitor C
47%
Sample receipt within stability99.1%
Reportable test yield
98.5%
Data packages delivered on time99.6%
Which partner doinvestigator sites prefer?
Central Laboratory Services
in 5 countries
1024Central Nervous
System
502InfectiousDiseases
322Hematology
979Oncology
391Respiratory
289Pathological
1003Endocrine/Metabolic
448Gastrointestinal
264
813ImmuneSystem
369Genital/Urinary
106
511Dermatology 344
Musculoskeletal
50 out of 50 of the best-selling drugs in 2013were developed in partnership with Covance.
Because we have unique insights in all therapeuticareas, you can unlock new solutions.
...to support your unique needs.
Therapeutic experience at your fingertips.
4,400 studies2, 2X more than any
other central lab.
Make better decisions, faster,by partnering with the industry leader.
Your ideal partner should have theflexibility and the experience...
Ophthalmology
Cardiovascular
the americas + 1.888.CovanCe + 1.609.452.4440
europe / africa + 00.800.2682.2682 Asia Pacific + 800.6568.3000
© Copyright 2015 Covance Inc. INFCLS002-0115
The global companion diagnostics market will be
valued at $5.6 billion in 2019 and is expected
to grow at a CAGR of 18.1% from 2013 to 2019.1
100%developed with Covance
Therapeutic
area
Type of diagnostic
partner selected
Pharma company
approach
Nature of
partnership
Percent of CDx licensing/partnership deals 2000-2012
CNSInfectiousdisease
Other
Oncology
Loyalpartner
Multi-partner
Start up/emerging
Established
Kit assay
Services
Undisclosed
Platformassay
0%developed without Covance
notes: 1 Transparency market research report 2 Based on Internal Covance data 2009-2013
Co-Development of the Companion Diagnostic with thetherapeutic saves time and aids commercialization.